Defunct Company
Total Trials
1
As Lead Sponsor
0
As Collaborator
Total Enrollment
20
NCT04759534
Application of PCSK9 Inhibitors in Patients With Heterozygous Familial Hypercholesterolemia
Phase: Phase 3
Role: Collaborator
Start: Sep 10, 2020
Completion: Nov 30, 2021